Jump to content

Simmerafil: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
Created page with ''''Simmerafil'''<ref>{{cite journal |last1=Odilov |first1=Abdullajon |last2=Liu |first2=Yin |last3=Hu |first3=Tianwen |last4=Jiang |first4=Xiangrui |last5=Suo |first5=Jin |last6=Tian |first6=Guanghui |last7=Yang |first7=Feipu |last8=Shen |first8=Jingshan |title=Facile and Cost-Effective Route for the Synthesis of Simmerafil |journal=Organic Process Research & Development |date=19 November 2021 |volume=25 |issue=11 |pages=2432–2437 |doi=10.1021/acs.oprd.1c...'
(No difference)

Revision as of 07:12, 9 November 2023

Simmerafil[1] (TPN171H) is a selective PDE5 inhibitor[2] in development for the treatment of erectile dysfunction[3] and pulmonary hypertension.[4]

References

  1. ^ Odilov, Abdullajon; Liu, Yin; Hu, Tianwen; Jiang, Xiangrui; Suo, Jin; Tian, Guanghui; Yang, Feipu; Shen, Jingshan (19 November 2021). "Facile and Cost-Effective Route for the Synthesis of Simmerafil". Organic Process Research & Development. 25 (11): 2432–2437. doi:10.1021/acs.oprd.1c00184. ISSN 1083-6160.
  2. ^ Qian, Hongjie; Chen, Qian; Liang, Liyu; Zou, Yang; Pu, Huahua; Xin, Liang; Song, Rong; Li, Tingting; Zhu, Huijuan; Wang, Yu; Tian, Guanghui; Shen, Jingshan; Jiang, Hualiang; Yu, Chen; Wang, Zhen; Jia, Jingying (2021). "A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects". Drug Design, Development and Therapy. 15: 2947–2959. doi:10.2147/DDDT.S308610. ISSN 1177-8881.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  3. ^ "Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction". www.clinicaltrials.gov. CTG Labs. Retrieved 9 November 2023.
  4. ^ Zhao, Congke; Hu, Liqing; He, Xiangrong; Li, Lijun; Yin, Minghui; Tettey, Abraham Terkpertey; Wang, Yu; Shen, Jingshan; Tang, Siyuan; Wu, Chunhui; Li, Qianbin; Wang, Zhen; Li, Xiaohui (1 August 2022). "TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats". Vascular Pharmacology. 145: 107017. doi:10.1016/j.vph.2022.107017. ISSN 1537-1891.